Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

All-Natural Spray Sunscreen Expands Goddess Garden Organics Reach

This article was originally published in The Tan Sheet

Executive Summary

Launching the first all-natural, chemical-free continuous spray sunscreen opened the door to mass retailers for Goddess Garden Organics, which sells organic sun care products. The product also speaks to some safety and efficacy concerns FDA raised about sunscreens in 2011.

You may also be interested in...



Senators Push FDA For SPF Cap, Spray Sunscreen Review

Nine Democrats led by Senator Jack Reed ask FDA to resolve sunscreen issues that remain in regulatory limbo. FDA needs to clarify “misconceptions about misleadingly high SPF labels beyond 50, where the increase in UV protection is relatively small,” the senators suggest.

Protein, Migrating Ingredients Help Sports Category Build Muscle

Increased consumer demand for protein and the migration of popular ingredients from adjacent categories are spurring growth in sports nutrition. Protein helped drive up sales double digits for powders and formulas and the overall category grew 46% from $17.6 billion in 2006 to $25.7 billion in 2011.

FDA Questions Spray Sunscreen Safety, Efficacy And Monograph Status

FDA could exclude increasingly popular spray sunscreens from the final monograph unless firms submit sufficient safety and efficacy data, according to an advanced notice of proposed rulemaking.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS106574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel